The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Grand Opportunity in Medications Development for Substance-Use Disorders (U01 - Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.
- Letter of Intent Due Dates: 30 days before the application due date
- Application Due Date(s): Applications will be accepted on a rolling basis, beginning on August 26, 2019.
PAR-19-327 Expiration Date September 2, 2022
Application budgets are limited to $5 million per year for direct costs.
The maximum period of support is 3 years